Dr. Rhodes is a pharmaceutical technologist with 23 years experience in combination product development including formulations and devices for pulmonary inhalation aerosol, nasal spray, transdermal patch, sustained release injection, and oral and ocular delivery systems for biopharmaceutical products and small molecules.
He has played a key role in the development of the commercial products, Byetta (exenatide injection for Type 2 diabetes, FDA 2005), Lusedra (propofol prodrug, FDA 2008), Bydureon (exenatide extended-release injectable suspension, FDA 2012), Myalept (metreleptin for severe lypodystrophy, FDA 2014), Afrezza (insulin inhalation powder for Type 1 and 2 diabetes, FDA 2014).
Dr. Rhodes has been responsible for product development including drug delivery R&D, formulation and process development, clinical supply and manufacturing, analytical and bioanalytical chemistry in companies including start-up companies Sensulin and SKS Ocular, and the publically traded companies Amylin Pharmaceuticals, Guilford Pharmaceuticals, and Mannkind Pharmaceuticals. In addition to leading technical functions, he has also been drug development team leader for drug delivery system and molecule development programs translating them from research through clinical proof-of-concept and readying them for commercialization.
In the last four years, Dr. Rhodes has served as an independent consultant and in 2014 founded Drug Delivery Experts, a pharmaceutical technology laboratory conducting R&D programs related to delivery technologies for its partners and collaborators. In his role as consultant and as technology leader, Dr. Rhodes has worked on numerous programs at the interface of research and development, facilitating the translation of research programs into clinical development. In this capacity, he has served as formulation and drug product development leader, CMC leader, and project strategist for proteins, peptides, and small molecules in a number of disease areas including diabetes, metabolic disease, cancer, retina, glaucoma, Alzheimer’s, and other CNS disorders.
Many of the programs he has enabled through consulting or as technology leader have been in complex formulations and delivery technologies. He has been responsible for delivery system development in the area of sustained release intravitreal injection, topical ocular formulations, nasal spray systems, and sustained release subcutaneous injectables for companies ranging from small startup to large pharma. Most of the project work involves peptide, protein, and antibody therapeutics, and small molecule programs when they require a complex delivery formulation or device.
Dr. Rhodes earned his Doctorate degree in physical organic chemistry from UCLA and completed his training with a Post Doctoral position at Yale University. He has a Bachelors degree in chemistry from New York University.